NDA (New Drug Application)
ANDA (Generic Application)
Track protection status across key markets to assess launch feasibility.
It is formulated by 1 pharmaceutical company such as ALNYLAM PHARMS INC. It is marketed under 1 brand name, including AMVUTTRA. Available in 1 different strength, such as EQ 25MG BASE/0.5ML (EQ 25MG BASE/0.5ML), and administered through 1 route including SOLUTION;SUBCUTANEOUS.
API availability: Loading API feasibility...
Licensing: 1 potential partnersUS Launch window: Loading launch window...
Stay ahead with worldwide patent expiry and latest updates.
FDA approval history for this ingredient
Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.
Key expiration dates for US patents covering this ingredient
Stay ahead with worldwide patent expiry insights, market data, and research updates.
Latest drug strengths approved by FDA
| Strength | Route of Administration | Companies | Latest Approval Date |
|---|
Patents approved by the FDA for the ingredient
|
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
|---|---|---|---|---|---|
| {"application_id":"77231","ingredient":"VUTRISIRAN SODIUM","trade_name":"AMVUTTRA","family_id":"5b7c622bdfe347008dc9","publication_number":"US10131907B2","cleaned_patent_number":"10131907","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-08-24","publication_date":"2018-11-20","legal_status":"Granted"} | US10131907B2 Molecular Formulation | 20 Nov, 2018 | Granted | 24 Aug, 2028 | |
| {"application_id":"77215","ingredient":"VUTRISIRAN SODIUM","trade_name":"AMVUTTRA","family_id":"b5231ff2f0c14a999e1d","publication_number":"US10806791B2","cleaned_patent_number":"10806791","drug_product_flag":"-","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-12-04","publication_date":"2020-10-20","legal_status":"Granted"} | US10806791B2 Molecular | 20 Oct, 2020 | Granted | 04 Dec, 2028 | |
| {"application_id":"77178","ingredient":"VUTRISIRAN SODIUM","trade_name":"AMVUTTRA","family_id":"b5231ff2f0c14a999e1d","publication_number":"US9370581B2","cleaned_patent_number":"9370581","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-12-04","publication_date":"2016-06-21","legal_status":"Granted"} | US9370581B2 Molecular Formulation | 21 Jun, 2016 | Granted | 04 Dec, 2028 | |
| {"application_id":"77210","ingredient":"VUTRISIRAN SODIUM","trade_name":"AMVUTTRA","family_id":"b5231ff2f0c14a999e1d","publication_number":"US8828956B2","cleaned_patent_number":"8828956","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-12-04","publication_date":"2014-09-09","legal_status":"Granted"} | US8828956B2 Molecular Formulation | 09 Sep, 2014 | Granted | 04 Dec, 2028 | |
| {"application_id":"77207","ingredient":"VUTRISIRAN SODIUM","trade_name":"AMVUTTRA","family_id":"b5231ff2f0c14a999e1d","publication_number":"US8106022B2","cleaned_patent_number":"8106022","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2029-12-12","publication_date":"2012-01-31","legal_status":"Granted"} | US8106022B2 Molecular Formulation | 31 Jan, 2012 | Granted | 12 Dec, 2029 | |
| {"application_id":"77345","ingredient":"VUTRISIRAN SODIUM","trade_name":"AMVUTTRA","family_id":"60a03570ba64479c9ca4","publication_number":"US9399775B2","cleaned_patent_number":"9399775","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-11-16","publication_date":"2016-07-26","legal_status":"Granted"} | US9399775B2 Molecular Formulation | 26 Jul, 2016 | Granted | 16 Nov, 2032 | |
| {"application_id":"77266","ingredient":"VUTRISIRAN SODIUM","trade_name":"AMVUTTRA","family_id":"60a03570ba64479c9ca4","publication_number":"US10570391B2","cleaned_patent_number":"10570391","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-11-16","publication_date":"2020-02-25","legal_status":"Granted"} | US10570391B2 Molecular Formulation | 25 Feb, 2020 | Granted | 16 Nov, 2032 | |
| {"application_id":"77258","ingredient":"VUTRISIRAN SODIUM","trade_name":"AMVUTTRA","family_id":"933a58c229784d938e3a","publication_number":"US11401517B2","cleaned_patent_number":"11401517","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-08-14","publication_date":"2022-08-02","legal_status":"Granted"} | US11401517B2 Molecular Formulation | 02 Aug, 2022 | Granted | 14 Aug, 2035 | |
| {"application_id":"77238","ingredient":"VUTRISIRAN SODIUM","trade_name":"AMVUTTRA","family_id":"933a58c229784d938e3a","publication_number":"US10612024B2","cleaned_patent_number":"10612024","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2035-08-14","publication_date":"2020-04-07","legal_status":"Granted"} | US10612024B2 Molecular Formulation | 07 Apr, 2020 | Granted | 14 Aug, 2035 | |
| {"application_id":"130710","ingredient":"VUTRISIRAN SODIUM","trade_name":"AMVUTTRA","family_id":"","publication_number":"US12049628B2","cleaned_patent_number":"12049628","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-07-28","publication_date":"2024-07-30","legal_status":"Granted"} | US12049628B2 Molecular Formulation | 30 Jul, 2024 | Granted | 28 Jul, 2036 | |
| {"application_id":"77172","ingredient":"VUTRISIRAN SODIUM","trade_name":"AMVUTTRA","family_id":"ec89c54faccf418a8049","publication_number":"US11286486B2","cleaned_patent_number":"11286486","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-07-28","publication_date":"2022-03-29","legal_status":"Granted"} | US11286486B2 Molecular Formulation | 29 Mar, 2022 | Granted | 28 Jul, 2036 | |
| {"application_id":"77143","ingredient":"VUTRISIRAN SODIUM","trade_name":"AMVUTTRA","family_id":"ec89c54faccf418a8049","publication_number":"US10683501B2","cleaned_patent_number":"10683501","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-07-28","publication_date":"2020-06-16","legal_status":"Granted"} | US10683501B2 Molecular Formulation | 16 Jun, 2020 | Granted | 28 Jul, 2036 | |
| {"application_id":"77171","ingredient":"VUTRISIRAN SODIUM","trade_name":"AMVUTTRA","family_id":"ec89c54faccf418a8049","publication_number":"US10208307B2","cleaned_patent_number":"10208307","drug_product_flag":"Y","drug_substance_flag":"Y","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2036-07-28","publication_date":"2019-02-19","legal_status":"Granted"} | US10208307B2 Molecular Formulation | 19 Feb, 2019 | Granted | 28 Jul, 2036 |
Latest clinical trials and research studies for this ingredient
| NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
|---|
Manufacturing Locations
Unlock access to all suppliers of Vutrisiran Sodium
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.